Skyhawk Therapeutics

Skyhawk Therapeutics, founded in Massachusetts, is dedicated to developing small molecule therapeutics aimed at treating cancer and neurological diseases. The company leverages its proprietary SKYSTAR® platform to create novel RNA-targeting small molecules, addressing some of the world's most challenging medical conditions. Skyhawk's mission is to revolutionize treatment options across neurology, oncology, and fibrosis, making significant strides in the pharmaceutical industry.

Notable affiliations include collaborations with leading pharmaceutical companies such as Bristol-Myers Squibb (BMS), Biogen, Genentech, Ipsen, Merck, Takeda, and Vertex. These partnerships have been instrumental in advancing Skyhawk's research and development efforts. Key achievements include the successful development of their unique platform and the initiation of multiple therapeutic programs. Skyhawk Therapeutics has made a substantial impact by pushing the boundaries of RNA-targeted therapies, offering new hope for patients with intractable diseases.